© 2024 Surgical Times. All Rights Reserved.
Washington, D.C., May 14, 2020—(FDA) FDA issues warning letters to two breast implant manufacturers as part of ongoing efforts to protect patients Allergan cited for failure to comply with post-approval study requirements; Ideal Implant Inc. cited for failures relating to quality system and medical device reporting regulations Today, the U.S. Food and Drug Administration issued warning letters to two breast implant manufacturers for failure to comply with various regulatory requirements. The agency issued a warning letter to breast implant manufacturer Allergan of Irvine, California, for failing to comply with requirements—under two separate premarket approval orders—to conduct post-approval studies to assess the long-term…